Close menu

July 29th, 2020 | 07:29 CEST

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

  • Health
Photo credits:

The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.

time to read: 2 minutes | Author: Mario Hose
ISIN: US09075V1026 , US2774614067 , CA30207T1049

Table of contents:

    Vaccine for COVID-19 under test

    BioNTech describes itself as a next generation immunotherapy company that is pioneering the development of therapies for cancer and other serious diseases. Its activities focus on combining a variety of modern therapeutic platforms and bioinformatics tools to rapidly advance the development of novel biopharmaceuticals. Based on its extensive expertise in the development of mRNA vaccines, BioNTech is also working with collaboration partners to develop various mRNA vaccine candidates for a number of infectious diseases.

    Together with Pfizer, BioNTech is working on the development of a vaccine for COVID-19, and the company recently announced that a vaccine candidate can participate in a Phase 2/3 study. The selection of candidates for this study has already been made based on data from the Phase 1/2 study in Germany and the USA. Up to 30,000 people aged between 18 and 85 years will participate in the study in approximately 120 study centers worldwide. If successful, up to 100 million vaccine doses will be made available by the end of the year and over 1.3 billion doses by the end of 2021.

    Expanding independence from China

    The capital market-oriented US President Donald Trump has announced that Eastman Kodak will receive a state loan of USD 765 million under the Defense Production Act. The company was formerly active in the photographic equipment sector and is known under the Kodak brand name. However, Kodak was not prepared for the success of digital photography and quickly fell into disarray. Management now plans to use the U.S. government's money to produce important ingredients for medicines.

    In connection with the Corona Pandemic, it became clear how dependent the world community is on Chinese producers. Restrictions in supply chains led to bottlenecks in the supply of equipment to the population. In addition to Kodak, 3M for the production of protective masks and General Motors for the production of respirators were already able to benefit from the 1950 law in connection with the Korean War.

    CEO increases stake in company

    EXMceuticals is a young life science company focused on the wellness and medical applications of cannabinoids and terpenes. The subsidiary EXM Portugal has licenses and permits for cannabis research for its existing laboratory and pilot refinery in Lisbon. The company has already completed research projects with Universidade Nova de Lisboa and Universidade Lusofona and has applied for P2020 research grants.

    In addition to the scientific mission, EXMceuticals claims that it is planning and building a much larger and additional plant in Portugal, which will be operated as an EU GMP refinery. Once this industrial refinery is completed and licensed, it will be used by the company as a base for the distribution of cannabis ingredients in the EU and North America on a commercial basis. The company's activities focus on the production of high-quality cannabis and hemp ingredients for the pharmaceutical, therapeutic, nutraceutical and cosmetic industries. The company intends to sell the produced ingredients to international medical markets. As part of a financing, CEO Jonathan Summers converted previous loans to EXMceuticals into shares of the company and now holds more than 16% of the voting rights.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 22nd, 2022 | 11:58 CEST

    Cardiol Therapeutics, Apple, Nel - Crisis-proof shares, despite inflation

    • Biotechnology
    • Covid19
    • Health

    Heart fluttering, pulse racing among investors, share prices highly volatile due to FED measures. Inflation and recessionary times are brutal for investors in the capital market. Three candidates have the potential to become profitable long-term investments: Cardiol Therapeutics, Apple and Nel. Cardiol Therapeutics fills the gap in the pharmaceutical market for the treatment of the heart disease, myocarditis. Apple is increasingly focusing on monitoring heart health, as cardiovascular disease is one of the leading causes of death in industrialized nations. In turn, these nations are struggling with extremely high energy prices. No wonder, then, that the Norwegian government is financially supporting the Company Nel to produce green hydrogen as quickly as possible...


    Commented by Nico Popp on November 25th, 2021 | 11:46 CET

    BB Biotech, Sativa Wellness, Carnival: Anti-aging as a megatrend

    • Health

    Anti-aging medicine is one of the most exciting research topics of our time. Already in 2018, Citigroup named the field as one of the ten rising topics of the future. While the pandemic has obscured many long-term ventures in the media, the work continues. People have long been optimizing and working to feel at least a little younger. We present three stocks related to biotechnology, anti-aging and wellness.


    Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET

    CureVac, Cardiol Therapeutics, Bayer - roaring profits!

    • Health

    The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.